Page last updated: 2024-10-28

ifosfamide and Carcinoma

ifosfamide has been researched along with Carcinoma in 71 studies

Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1."9.11A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004)
"The objectives of this study were to determine the efficacy, organ-preservation rate, and safety of intraarterial (IA) cisplatin in combination with intravenous paclitaxel and ifosfamide in patients with locally advanced carcinoma of the paranasal sinuses who required orbital exenteration or major craniofacial resection for complete tumor resection."9.10Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. ( Blumenschein, G; Clayman, G; Diaz, EM; Garden, AS; Gillenwater, A; Ginsberg, LE; Glisson, BS; Goepfert, H; Hong, WK; Kies, MS; Lippman, SM; Liu, DD; Morrison, WH; Papadimitrakopoulou, VA; Schommer, D, 2003)
"A phase I or II trial was conducted to assess the toxicity and the efficacy of a tandem high dose chemotherapy combining ifosfamide, carboplatin, and teniposide in patients with poor prognosis ovarian carcinoma."9.08Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. ( André, T; Bouleuc, C; Hannoun, L; Houry, S; Izrael, V; Lefranc, JP; Lotz, JP; Macovei, C; Touboul, E; Uzan, S, 1996)
"A phase II trial was performed to evaluate the efficacy and toxicity of a combination of cisplatin (CDDP) and ifosfamide (IFX) as neoadjuvant chemotherapy in advanced cervical carcinoma (ACC)."9.08Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. ( Arroyo, A; Castaldi, J; Cuevas, MA; Ferreyra, R; Focaccia, G; Lacava, J; Leone, B; Machiavelli, M; Perez, J; Rabinovich, M; Romero, A; Suttora, G; Vallejo, C, 1996)
"A phase II trial was performed to evaluate the efficacy and toxicity of a combination of ifosfamide (IFX) and mitoxantrone (MXN) as first-line chemotherapy for metastatic breast carcinoma."9.07Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer. ( Bianco, A; Cuevas, MA; Lacava, JA; Leone, BA; Machiavelli, M; Perez, JE; Rabinovich, MG; Rodriguez, R; Romero, A; Vallejo, CT, 1993)
"A phase II trial of ifosfamide (IFX) and mesna was conducted by the GOG in patients with recurrent or advanced nonsquamous carcinoma of the cervix."9.07Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. ( Blessing, JA; DiSaia, PJ; McGuire, WP; Sutton, GP, 1993)
"Phase II trial in metastatic urothelial carcinoma using a novel combination chemotherapy regimen consisting of vinblastine, ifosfamide, and gallium nitrate (VIG)."9.07Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. ( Ansari, R; Dreicer, R; Einhorn, LH; Gonin, R; Loehrer, PJ; Roth, BJ, 1994)
"Ifosfamide (isophosphamide) and mesna (2-mercaptoethane sodium sulfonate) were administered intravenously at monthly intervals to 46 patients with advanced epithelial ovarian carcinoma refractory to or recurrent after cisplatin-containing combination chemotherapy."9.06Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. ( Berman, ML; Blessing, JA; Homesley, HD; Malfetano, J; Sutton, GP, 1989)
"To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy."7.81[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015)
"Thirty patients aged 34-69 years (median 56) with previously untreated FIGO Stage III and IV ovarian carcinoma were given carboplatin (400 mg/m2) and ifosfamide (5 g/m2) with mesna every 28 days for a median of 3 cycles, followed, where possible, by laparotomy."7.68Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. ( Green, JA; Lim, JT, 1993)
"A Phase II study of VP-16 (etoposide), ifosfamide/mesna, and cisplatin (VIP) in advanced and recurrent carcinoma of the cervix was initiated March 1989."7.68Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. ( Kredentser, DC, 1991)
"The Gastrointestinal Tumor Study Group (GITSG) investigated the efficacy of ifosfamide with mesna uroprotection in 30 patients with advanced inoperable pancreatic carcinoma that was confirmed histologically."7.67Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. ( , 1989)
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)."7.66[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983)
"Ifosfamide is a cyclophosphamide analogue synthesized in the 1960s with antineoplastic activity demonstrated in early broad-ranging phase I studies conducted in Germany in the 1970s."6.38Ifosfamide and mesna in epithelial ovarian carcinoma. ( Sutton, G, 1993)
"Etoposide (100 mg/m2) was given i."5.28A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. ( Kaern, J; Tropé, C; Vergote, I; Vossli, S, 1990)
"To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1."5.11A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004)
" Ifosfamide has shown significant activity as a single agent in head and neck squamous carcinoma."5.10Neoadjuvant chemotherapy with ifosfamide and cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience. ( Bakshi, AV; Deshmukh, CD; Mazumdar, AT; Mistry, RC; Pai, VR; Parikh, DM; Parikh, PM; Pathak, KA, 2003)
"The objectives of this study were to determine the efficacy, organ-preservation rate, and safety of intraarterial (IA) cisplatin in combination with intravenous paclitaxel and ifosfamide in patients with locally advanced carcinoma of the paranasal sinuses who required orbital exenteration or major craniofacial resection for complete tumor resection."5.10Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. ( Blumenschein, G; Clayman, G; Diaz, EM; Garden, AS; Gillenwater, A; Ginsberg, LE; Glisson, BS; Goepfert, H; Hong, WK; Kies, MS; Lippman, SM; Liu, DD; Morrison, WH; Papadimitrakopoulou, VA; Schommer, D, 2003)
"A phase I or II trial was conducted to assess the toxicity and the efficacy of a tandem high dose chemotherapy combining ifosfamide, carboplatin, and teniposide in patients with poor prognosis ovarian carcinoma."5.08Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. ( André, T; Bouleuc, C; Hannoun, L; Houry, S; Izrael, V; Lefranc, JP; Lotz, JP; Macovei, C; Touboul, E; Uzan, S, 1996)
"A phase II trial was performed to evaluate the efficacy and toxicity of a combination of cisplatin (CDDP) and ifosfamide (IFX) as neoadjuvant chemotherapy in advanced cervical carcinoma (ACC)."5.08Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. ( Arroyo, A; Castaldi, J; Cuevas, MA; Ferreyra, R; Focaccia, G; Lacava, J; Leone, B; Machiavelli, M; Perez, J; Rabinovich, M; Romero, A; Suttora, G; Vallejo, C, 1996)
"We have reported the results of a previous Phase II trial of two courses of neoadjuvant mitomycin (6 mg/m2), ifosfamide (3 g/m2) and cisplatin (50 mg/m2) (MIC) in squamous or anaplastic carcinoma of the oesophagus."5.08A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus. ( Cullen, MH; Darnton, SJ; Matthews, HR; McAleer, JA; McManus, KG; Steyn, RS, 1998)
"A phase II trial of ifosfamide (IFX) and mesna was conducted by the GOG in patients with recurrent or advanced nonsquamous carcinoma of the cervix."5.07Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. ( Blessing, JA; DiSaia, PJ; McGuire, WP; Sutton, GP, 1993)
"A phase II trial was performed to evaluate the efficacy and toxicity of a combination of ifosfamide (IFX) and mitoxantrone (MXN) as first-line chemotherapy for metastatic breast carcinoma."5.07Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer. ( Bianco, A; Cuevas, MA; Lacava, JA; Leone, BA; Machiavelli, M; Perez, JE; Rabinovich, MG; Rodriguez, R; Romero, A; Vallejo, CT, 1993)
"Thirty-six patients with recurrent carcinoma of the head and neck and no prior exposure to chemotherapy were treated with Ifosfamide."5.07Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. ( Barón, FJ; Buesa, JM; Esteban, E; Estrada, E; Fernández, R; Gracia, M; Lacave, AJ; Palacio, I, 1991)
"Phase II trial in metastatic urothelial carcinoma using a novel combination chemotherapy regimen consisting of vinblastine, ifosfamide, and gallium nitrate (VIG)."5.07Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. ( Ansari, R; Dreicer, R; Einhorn, LH; Gonin, R; Loehrer, PJ; Roth, BJ, 1994)
"Ifosfamide (isophosphamide) and mesna (2-mercaptoethane sodium sulfonate) were administered intravenously at monthly intervals to 46 patients with advanced epithelial ovarian carcinoma refractory to or recurrent after cisplatin-containing combination chemotherapy."5.06Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. ( Berman, ML; Blessing, JA; Homesley, HD; Malfetano, J; Sutton, GP, 1989)
"To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy."3.81[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015)
"Thirty patients aged 34-69 years (median 56) with previously untreated FIGO Stage III and IV ovarian carcinoma were given carboplatin (400 mg/m2) and ifosfamide (5 g/m2) with mesna every 28 days for a median of 3 cycles, followed, where possible, by laparotomy."3.68Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. ( Green, JA; Lim, JT, 1993)
"A Phase II study of VP-16 (etoposide), ifosfamide/mesna, and cisplatin (VIP) in advanced and recurrent carcinoma of the cervix was initiated March 1989."3.68Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. ( Kredentser, DC, 1991)
"The Gastrointestinal Tumor Study Group (GITSG) investigated the efficacy of ifosfamide with mesna uroprotection in 30 patients with advanced inoperable pancreatic carcinoma that was confirmed histologically."3.67Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. ( , 1989)
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)."3.66[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983)
"Twenty-one chemotherapy naive ovarian cancer patients with stage III and minimal residual tumor were treated with cisplatin 75 mg/m2 and mitoxantrone 15 mg/m2 (1st day) by intraperitoneal (i."2.69Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer. ( Aydmer, A; Bengisu, E; Berkman, S; Saip, P; Salihoğlu, Y; Topuz, E, 1998)
"Etoposide was given at 150 mg/m2 every 12 h for six doses on days 1-3."2.69High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. ( Aleman, A; Anderlini, P; Bast, RC; Bevers, M; Bodurka-Bevers, D; Boyer, J; Burke, T; Champlin, RE; Donato, ML; Freedman, R; Gajewski, JG; Gershenson, D; Giralt, S; Ippoliti, C; Korbling, M; Lauppe, J; Levenback, C; Molldrem, J; Ueno, N; Wharton, JT; Wolf, J, 2000)
"Radiation-induced osteosarcomas are a recognized complication of radiation therapy."2.53Radiation-induced osteosarcoma of the skull base after radiation therapy in a patient with nasopharyngeal carcinoma: a case report and review of the literature. ( Benjaafar, N; Echchikhi, Y; Kebdani, T; Loughlimi, H; Touil, A, 2016)
"Intraperitoneal carcinomatosis (PC) may occur with several tumor entities."2.49Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy. ( Binder, S; Keese, M; Lewis, AL; Löhr, JM, 2013)
"In advanced epithelial ovarian cancer, it has been tested in association with cisplatin, achieving results equal, if not better than cyclophosphamide, with acceptable toxicity."2.42Ifosfamide in the treatment of malignant epithelial ovarian tumors. ( Fei, F; Fruscio, R; Lissoni, AA; Rossi, R; Villa, A; Zani, G, 2003)
"Thymomas and thymic carcinomas are unique tumors of the anterior mediastinum."2.41Thymic malignancies. ( Loehrer, PJ; Wick, MR, 2001)
" Such simultaneous administration enabled us to substantially increase the dosage intensity of both, thereby increasing the effectiveness of each drug."2.40Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. ( Lackman, RD; Weiss, AJ, 1997)
"In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses."2.38Gynecologic Oncology Group studies with ifosfamide. ( Blessing, JA; Homesley, H; Manetta, A; McGuire, W; Sutton, GP, 1992)
"Ifosfamide is a cyclophosphamide analogue synthesized in the 1960s with antineoplastic activity demonstrated in early broad-ranging phase I studies conducted in Germany in the 1970s."2.38Ifosfamide and mesna in epithelial ovarian carcinoma. ( Sutton, G, 1993)
"NUT carcinoma is an extremely rare disease and yet extremely aggressive with 2-year survival of only approximately 19% and median survival of 6 to 9 months."1.56Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation. ( Chang, JS; Pan, M, 2020)
"treatment with ifosfamide alone or ifosfamide combined with microencapsulated CYP2B1 expressing cells."1.34Targeted intraabdominal chemotherapy for peritoneal carcinomatosis. ( Löhr, M; Samel, S, 2007)
"A total of 25 patients with epithelial ovarian cancer were treated with second-line carboplatin, etoposide, and ifosfamide (ICE) following failure of first-line cisplatin-based combination chemotherapy."1.29Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer. ( Fanning, J; Hilgers, RD; Hutson, E, 1994)
"These were neuroepithelioma, lymphoma, desmoplastic small-cell tumor, melanoma, and clear-cell sarcoma."1.29Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. ( Bosl, GJ; Chaganti, RS; Mazumdar, M; Motzer, RJ; Reuter, VE; Rodriguez, E, 1995)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."1.28Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990)
"Etoposide (100 mg/m2) was given i."1.28A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. ( Kaern, J; Tropé, C; Vergote, I; Vossli, S, 1990)
"A 62-year-old woman developed subacute renal failure after the repeated administration of ifosfamide (IFX), despite its combination with continuous sodium 2-mercaptoethane sulfonate (mesna) infusion."1.28Severe renal failure following high-dose ifosfamide and mesna. ( de Jong, PE; Elema, JD; Mulder, NH; Willemse, PH, 1989)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."1.28Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1989)

Research

Studies (71)

TimeframeStudies, this research(%)All Research%
pre-199011 (15.49)18.7374
1990's35 (49.30)18.2507
2000's14 (19.72)29.6817
2010's7 (9.86)24.3611
2020's4 (5.63)2.80

Authors

AuthorsStudies
Muramatsu, J1
Takada, K1
Sugita, S1
Tsuchiya, T1
Yamamoto, K1
Takagi, M1
Murase, K1
Ameda, S1
Arihara, Y1
Miyanishi, K1
Sakata, KI1
Kato, J1
Lemelle, L1
Flaadt, T1
Fresneau, B1
Moya-Plana, A1
Timmermann, B1
Roganovic, J1
Ferrari, A1
Fichera, G1
Lauer, UM1
Ben-Ami, T1
Schneider, DT1
Vokuhl, C1
Bolle, S1
Fox, E1
DuBois, SG1
Rodriguez-Galindo, C1
Bisogno, G1
Surun, A1
Brecht, IB1
Orbach, D1
Sánchez-Romero, C1
Paes de Almeida, O1
Díaz Molina, JP1
Carlos, R1
Pan, M1
Chang, JS1
Binder, S1
Lewis, AL1
Löhr, JM1
Keese, M1
Schneider, C1
Kamaly-Asl, I1
Ramaswamy, V1
Lafay-Cousin, L1
Kulkarni, AV1
Rutka, JT1
Remke, M1
Coluccia, D1
Tabori, U1
Hawkins, C1
Bouffet, E1
Taylor, MD1
Vulsteke, C1
Lurquin, E1
Debiec-Rychter, M1
Gheysens, O1
Nuyts, S1
Schoenaers, J1
Politis, C1
Mebis, J1
Hauben, E1
Clement, PM1
Hu, S1
He, X1
Dong, M1
Jia, B1
Zhou, S1
Yang, J1
Yang, S1
Zhang, C1
Liu, P1
Qin, Y1
Gui, L1
Matsuo, K1
Takazawa, Y1
Ross, MS1
Elishaev, E1
Podzielinski, I1
Yunokawa, M1
Sheridan, TB1
Bush, SH1
Klobocista, MM1
Blake, EA1
Takano, T1
Matsuzaki, S1
Baba, T1
Satoh, S1
Shida, M1
Nishikawa, T1
Ikeda, Y1
Adachi, S1
Yokoyama, T1
Takekuma, M1
Fujiwara, K2
Hazama, Y1
Kadogami, D1
Moffitt, MN1
Takeuchi, S1
Nishimura, M1
Iwasaki, K1
Ushioda, N1
Johnson, MS1
Yoshida, M1
Hakam, A1
Li, SW1
Richmond, AM1
Machida, H1
Mhawech-Fauceglia, P1
Ueda, Y1
Yoshino, K1
Yamaguchi, K1
Oishi, T1
Kajiwara, H1
Hasegawa, K1
Yasuda, M1
Kawana, K1
Suda, K1
Miyake, TM1
Moriya, T1
Yuba, Y1
Morgan, T1
Fukagawa, T1
Wakatsuki, A1
Sugiyama, T1
Pejovic, T1
Nagano, T1
Shimoya, K1
Andoh, M1
Shiki, Y1
Enomoto, T1
Sasaki, T1
Mikami, M1
Shimada, M1
Konishi, I1
Kimura, T1
Post, MD1
Shahzad, MM1
Im, DD1
Yoshida, H1
Omatsu, K1
Ueland, FR1
Kelley, JL1
Karabakhtsian, RG1
Roman, LD1
Echchikhi, Y1
Loughlimi, H1
Touil, A1
Kebdani, T1
Benjaafar, N1
Lin, HH1
Lin, JN1
Grushka, JR1
Ryckman, J1
Mueller, C1
Roessingh, Ade B1
Walton, JM1
St Vil, D1
Laberge, JM1
Bernard, C1
Nguyen, VH1
Puligandla, PS1
Burnside, N1
MacGowan, SW1
Misiura, K1
Szymanowicz, D1
Kuśnierczyk, H1
Wietrzyk, J1
Opolski, A1
Pai, VR1
Mazumdar, AT1
Deshmukh, CD1
Bakshi, AV1
Parikh, DM1
Parikh, PM1
Mistry, RC1
Pathak, KA1
Lissoni, AA1
Fei, F1
Rossi, R1
Fruscio, R1
Villa, A1
Zani, G1
Papadimitrakopoulou, VA1
Ginsberg, LE1
Garden, AS1
Kies, MS1
Glisson, BS1
Diaz, EM1
Clayman, G1
Morrison, WH1
Liu, DD1
Blumenschein, G1
Lippman, SM1
Schommer, D1
Gillenwater, A1
Goepfert, H1
Hong, WK1
Chua, DT1
Sham, JS1
Au, GK1
Zylberberg, B1
Dormont, D1
Madelenat, P1
Daraï, E1
Samel, S1
Löhr, M1
Mishra, A1
El-Naggar, AK1
DeMonte, F1
Hanna, EY1
Saiers, JH1
Slavik, M1
Joss, RA1
Cavalli, F1
Goldhirsch, A1
Mermillod, B1
Brunner, KW1
Matthiessen, W1
Stempinski, E1
Göbel, D1
Thalmann, U1
Einhorn, LH1
Roth, BJ1
Ansari, R1
Dreicer, R1
Gonin, R1
Loehrer, PJ2
Motzer, RJ1
Rodriguez, E1
Reuter, VE1
Bosl, GJ1
Mazumdar, M1
Chaganti, RS1
Leo, AD1
Biganzoli, L1
Bohm, S1
Lupi, G1
Oriana, S1
Riboldi, G1
Spatti, G1
Vicario, G1
Di Re, F1
Bajetta, E1
Conte, PF1
Gadducci, A1
Fioretti, P1
Bruzzone, M1
Brunetti, I1
Ragni, N1
Fanning, J1
Hilgers, RD1
Hutson, E1
Sutton, G1
Pierga, JY1
Kalifa, C1
Terrier-Lacombe, MJ1
Habrand, JL1
Lemerle, J1
Lim, JT1
Green, JA1
Lorusso, V2
Catino, A2
Leone, B3
Rabinovich, M2
Gargano, G2
Paradiso, A1
De Lena, M2
Perez, JE1
Machiavelli, M3
Leone, BA1
Romero, A2
Rabinovich, MG1
Vallejo, CT1
Bianco, A1
Lacava, JA1
Rodriguez, R1
Cuevas, MA2
Sutton, GP5
Blessing, JA5
DiSaia, PJ1
McGuire, WP1
Heideman, RL1
Douglass, EC1
Langston, JA1
Krischer, JP1
Burger, PC1
Kovnar, EH1
Kun, LE1
Friedman, HS1
Kadota, R1
Vallejo, C2
Perez, J1
Lacava, J1
Focaccia, G1
Ferreyra, R1
Suttora, G1
Castaldi, J1
Arroyo, A1
Lotz, JP1
Bouleuc, C1
André, T1
Touboul, E1
Macovei, C1
Hannoun, L1
Lefranc, JP1
Houry, S1
Uzan, S1
Izrael, V1
Perkins, JB1
Effenbein, GJ1
Fields, KK1
Thigpen, T2
Vance, R1
Khansur, T1
Malamud, F1
Stein, ME2
Ruff, P1
Weaving, A1
Fried, J1
Bezwoda, WR1
Erkisi, M1
Erkurt, E1
Ozbarlas, S1
Burgut, R1
Doran, F1
Seyrek, E1
Teicher, BA1
Holden, SA1
Goff, DA1
Wright, JE1
Tretyakov, O1
Ayash, LJ1
Weiss, AJ1
Lackman, RD1
Kaijser, GP1
Beijnen, JH1
Bult, A1
Keizer, HJ1
Underberg, WJ1
Drumea, K1
Veyhl, M1
Wagner, K1
Volk, C1
Gorboulev, V1
Baumgarten, K1
Weber, WM1
Schaper, M1
Bertram, B1
Wiessler, M1
Koepsell, H1
Di Vagno, G1
Manzione, L1
Palmeri, S1
Nacci, G1
Bilancia, D1
Leonardi, V1
Loverro, G1
Selvaggi, L1
Topuz, E1
Saip, P1
Aydmer, A1
Salihoğlu, Y1
Berkman, S1
Bengisu, E1
Aziz, Z1
Zahid, M1
Ud Din Ahmed, Z1
Arshad, T1
Steyn, RS1
Darnton, SJ1
McManus, KG1
McAleer, JA1
Cullen, MH1
Matthews, HR1
Roques, B1
Pichon, A1
De Laroche, G1
Garnier, JF1
Jacquin, JP1
Donato, ML1
Gershenson, D1
Ippoliti, C1
Wharton, JT1
Bast, RC1
Aleman, A1
Anderlini, P1
Gajewski, JG1
Giralt, S1
Molldrem, J1
Ueno, N1
Lauppe, J1
Korbling, M1
Boyer, J1
Bodurka-Bevers, D1
Bevers, M1
Burke, T1
Freedman, R1
Levenback, C1
Wolf, J1
Champlin, RE1
Wick, MR1
Günzburg, WH1
Salmons, B1
Ritter, S1
Schröder, HJ1
Kokron, O1
Titscher, R1
Micksche, M1
Cerni, C1
Wrba, H1
Mitrou, PS1
Fischer, M1
Mitrou, G1
Röttger, P1
Buxton, EJ1
Lambuth, BW1
Vance, RB1
Manetta, A1
Homesley, H1
McGuire, W1
Markman, M1
Hakes, T1
Reichman, B1
Lewis, JL1
Rubin, S1
Jones, W1
Almadrones, L1
Pizzuto, F1
Hoskins, W1
Kredentser, DC1
Buesa, JM1
Fernández, R1
Esteban, E1
Estrada, E1
Barón, FJ1
Palacio, I1
Gracia, M1
Lacave, AJ1
Photopulos, G2
Berman, ML3
Homesley, HD3
Tropé, C1
Kaern, J1
Vergote, I1
Vossli, S1
Willemse, PH1
de Jong, PE1
Elema, JD1
Mulder, NH1
Malfetano, J1
Peake, MD1
Parker, D1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and IL2 for Treatment of Advanced Solid Tumors[NCT04770207]Phase 2100 participants (Anticipated)Interventional2020-11-01Recruiting
Phase I Trial of High-dose Topotecan in Association With Carboplatin, With Peripheral Blood Stem Cell Support in Patients With First Relapsed Ovarian Carcinoma Without Platinum-treatment Since 6-12 Months[NCT01177501]Phase 13 participants (Actual)Interventional2009-04-30Terminated (stopped due to choice of the principal investigator)
Conventional Dose Chemotherapy for Ovarian Cancer Supported by Autologous Haematopoietic Stem Cell Transfusion[NCT05401162]40 participants (Anticipated)Interventional2022-04-15Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

14 reviews available for ifosfamide and Carcinoma

ArticleYear
Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.
    World journal of gastroenterology, 2013, Nov-21, Volume: 19, Issue:43

    Topics: Animals; Antineoplastic Agents; Carcinoma; Cell- and Tissue-Based Therapy; Chemoembolization, Therap

2013
Radiation-induced osteosarcoma of the skull base after radiation therapy in a patient with nasopharyngeal carcinoma: a case report and review of the literature.
    Journal of medical case reports, 2016, Dec-01, Volume: 10, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diplopia; Doxorubicin;

2016
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
    Journal of pediatric surgery, 2009, Volume: 44, Issue:5

    Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Ch

2009
Malignant primary cardiac tumours.
    Interactive cardiovascular and thoracic surgery, 2012, Volume: 15, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures;

2012
Ifosfamide in the treatment of malignant epithelial ovarian tumors.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents, Alkylating; Carcinoma; Female; Humans; Ifosfamide; Ovarian Neoplasms; Sarcoma

2003
New agents in non-small cell lung cancer.
    Cancer treatment reviews, 1984, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti

1984
Ifosfamide and mesna in epithelial ovarian carcinoma.
    Gynecologic oncology, 1993, Volume: 51, Issue:1

    Topics: Carcinoma; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans;

1993
Carcinoma of the choroid plexus: a pediatric experience.
    Medical and pediatric oncology, 1993, Volume: 21, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Chil

1993
The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti

1996
Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations.
    American journal of clinical oncology, 1997, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Doxorubicin; Dr

1997
Thymic malignancies.
    Cancer treatment and research, 2001, Volume: 105

    Topics: Adrenal Cortex Hormones; Agammaglobulinemia; Antineoplastic Agents; Antineoplastic Combined Chemothe

2001
Novel clinical strategies for the treatment of pancreatic carcinoma.
    Trends in molecular medicine, 2001, Volume: 7, Issue:1

    Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antineoplastic Agents; Bile; Biotransformation; Canc

2001
The role of ifosfamide in gynecologic cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Genital Neoplasms, Female; Humans

1992
Gynecologic Oncology Group studies with ifosfamide.
    Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 12

    Topics: Adenocarcinoma; Carcinoma; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Female; Genita

1992

Trials

27 trials available for ifosfamide and Carcinoma

ArticleYear
Neoadjuvant chemotherapy with ifosfamide and cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience.
    Medical oncology (Northwood, London, England), 2003, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro

2003
Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma.
    Cancer, 2003, Nov-15, Volume: 98, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp

2003
A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
    Head & neck, 2004, Volume: 26, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp

2004
First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
    European journal of gynaecological oncology, 2004, Volume: 25, Issue:3

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Ca

2004
New agents in non-small cell lung cancer.
    Cancer treatment reviews, 1984, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti

1984
Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cal

1994
An intensive treatment with mitoxantrone and ifosfamide in second-line therapy of epithelial ovarian cancer.
    Tumori, 1994, Dec-31, Volume: 80, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule; Fema

1994
Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma.
    European journal of gynaecological oncology, 1994, Volume: 15, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cobalt

1994
Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Drug Admin

1993
Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
    Gynecologic oncology, 1993, Volume: 49, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Female; Humans; Ifosfamide; Mesna; Middle Aged; Uterine Cerv

1993
A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.
    Journal of neuro-oncology, 1995, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Child

1995
Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma.
    American journal of clinical oncology, 1996, Volume: 19, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo

1996
Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma.
    Cancer, 1996, Jun-15, Volume: 77, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Car

1996
Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylatin

1996
A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa.
    American journal of clinical oncology, 1996, Volume: 19, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined

1996
The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma.
    Journal of chemotherapy (Florence, Italy), 1996, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas

1996
Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
    Gynecologic oncology, 1998, Volume: 68, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carb

1998
Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer.
    European journal of gynaecological oncology, 1998, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Feasibility Studi

1998
Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
    Australian and New Zealand journal of medicine, 1998, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, A

1998
A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1998, Volume: 10, Issue:3

    Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Al

1998
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
    Bone marrow transplantation, 2000, Volume: 25, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carcinoma; Combined

2000
[Clinical experience with the cytostatic drug ifosfamide].
    Die Medizinische Welt, 1977, Sep-02, Volume: 28, Issue:35

    Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Drug Ther

1977
[Clinical experiences with Holoxan in small cell carcinoma of the bronchus (author's transl)].
    Osterreichische Zeitschrift fur Onkologie. Austrian journal of oncology, 1977, Nov-15, Volume: 4, Issue:5-6

    Topics: Bronchial Neoplasms; Carcinoma; Cyclophosphamide; Humans; Ifosfamide; Male; Neoplasm Metastasis; Qua

1977
Experience with bleomycin, ifosfamide, and cisplatin in primary and recurrent cervical cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo

1992
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:2

    Topics: Acute Kidney Injury; Adult; Aged; Carcinoma; Drug Evaluation; Drug Resistance; Female; Humans; Ifosf

1992
Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Evaluation; Head and Ne

1991
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:11

    Topics: Carcinoma; Drug Evaluation; Female; Humans; Ifosfamide; Leukocyte Count; Mercaptoethanol; Mesna; Mul

1989

Other Studies

31 other studies available for ifosfamide and Carcinoma

ArticleYear
Complete Response Induced by Concurrent Chemoradiotherapy in a Patient with NUT Carcinoma.
    Internal medicine (Tokyo, Japan), 2022, Apr-15, Volume: 61, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Hum

2022
NUT Carcinoma in Children and Adolescents: The Expert European Standard Clinical Practice Harmonized Recommendations.
    Journal of pediatric hematology/oncology, 2023, 05-01, Volume: 45, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Child; Cisplatin; Cyclophosph

2023
Pediatric nasal NK/T-cell lymphoma microscopically mimicking carcinoma.
    International journal of dermatology, 2020, Volume: 59, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma; Chemorad

2020
Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation.
    The Permanente journal, 2020, Volume: 25

    Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma; Etoposide; Hu

2020
Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas.
    Journal of neurosurgery. Pediatrics, 2015, Volume: 16, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Carboplatin; Carcinoma; Chemot

2015
First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation.
    Journal of chemotherapy (Florence, Italy), 2016, Volume: 28, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Cisplatin; Doxorub

2016
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:8

    Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytid

2015
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:7

    Topics: Adult; Aged; Carcinoma; Carcinosarcoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Human

2016
Tender nodules on the palms and soles after chemotherapy.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008, Jun-03, Volume: 178, Issue:12

    Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Drug-Related Side Effects and Adverse Reactions; Epiru

2008
Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).
    Acta biochimica Polonica, 2002, Volume: 49, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma; Chromatography, High Pressure Liquid; Cytochrome P-450 En

2002
Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
    Cancer treatment and research, 2007, Volume: 134

    Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Carcinoma; Cell Line, Tumor; Ce

2007
Endodermal sinus tumor of the paranasal sinuses.
    Head & neck, 2008, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Endodermal Sinus Tumor; Humans

2008
Pilot study of intravenous ifosfamide plus oral acetylcysteine in the treatment of non-small cell lung cancer.
    Veterinary and human toxicology, 1981, Volume: 23, Issue:Suppl 1

    Topics: Acetylcysteine; Adenocarcinoma; Administration, Oral; Carcinoma; Carcinoma, Small Cell; Carcinoma, S

1981
[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide].
    Deutsche medizinische Wochenschrift (1946), 1983, May-27, Volume: 108, Issue:21

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophos

1983
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Carcinoma

1995
Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer.
    American journal of clinical oncology, 1994, Volume: 17, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Evaluation

1994
Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1993, Volume: 5, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, A

1993
Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Humans;

1993
Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro

1996
Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine.
    Journal of chromatography. B, Biomedical sciences and applications, 1997, Mar-07, Volume: 690, Issue:1-2

    Topics: Adult; Antineoplastic Agents, Alkylating; Carcinoma; Chromatography, Gas; Cyclophosphamide; Humans;

1997
Ifosfamide/cisplatin-based chemotherapy in metastatic undifferentiated nasopharyngeal carcinoma.
    The Laryngoscope, 1997, Volume: 107, Issue:11 Pt 1

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma;

1997
Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1.
    Proceedings of the National Academy of Sciences of the United States of America, 1998, Mar-17, Volume: 95, Issue:6

    Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carcinoma; Glucose; Humans; Ifosfa

1998
[Intra-abdominal desmoplastic small round-cell tumors. An entity among peritoneal carcinomatoses in young adults].
    Gastroenterologie clinique et biologique, 2000, Volume: 24, Issue:3

    Topics: Abdominal Neoplasms; Abdominal Pain; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protoco

2000
The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB x NZW) mice. II. Emergence of tumors in young animals treated with azathioprine and ifosfamide, including a histologic assessment of the neoplasms.
    Arzneimittel-Forschung, 1979, Volume: 29, Issue:4

    Topics: Animals; Azathioprine; Carcinogens; Carcinoma; Cyclophosphamide; Female; Hyperplasia; Ifosfamide; Ly

1979
Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.
    Gynecologic oncology, 1991, Volume: 43, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female

1991
Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Antineoplastic Agents; Carcinoma; Drug Evaluation; Female; Humans; Ifosfamide; Mercaptoethanol; Mesn

1990
A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Evaluation;

1990
Severe renal failure following high-dose ifosfamide and mesna.
    Cancer chemotherapy and pharmacology, 1989, Volume: 23, Issue:5

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma; Dose-Respons

1989
Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group.
    Cancer, 1989, Nov-15, Volume: 64, Issue:10

    Topics: Adult; Aged; Carcinoma; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Male; Mesna; Nervous

1989
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci

1989
Ifosfamide as single-agent chemotherapy in inoperable non-small-cell lung cancer.
    Lancet (London, England), 1985, Aug-31, Volume: 2, Issue:8453

    Topics: Adult; Aged; Carcinoma; Cyclophosphamide; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged

1985